International Journal of Progressive Sciences and Technologies (IJPSAT)
ISSN: 2509-0119.

Vol. 43 No. 1 February 2024, pp. 35-57

Updates of Pathogenesis, Diagnosis, and Treatment of Immune Thrombocytopenia

Critical Review

Maged Naser[1], Mohamed M. Nasr[2], and Lamia H. Shehata[3]

[1]Mazahmiya Hospital, Ministry of Health, Kingdom of Saudi Arabia, Department of ob/gyn,

[2]King Fahd Hospital, Ministry of Health, Kingdom of Saudi Arabia, Department of Surgery,

[3]Care National Hospital, Department of Radiology

Abstract – Primary immune thrombocytopenia is an autoimmune disorder associated with a decreased prephiral blood platelet count. The phenotype is variable with a few instances struggling no bleeding while others have extreme bleeding which may be deadly. Variability in clinical behaviour and remedy responses reflects its complicated pathophysiology. Traditionally the management has relied heavily on immune suppression. latest studies have shown that the older empirical immune suppressants fail to adjust the natural history of the complaint and are associated with a bad exceptional life for patients. More recent remedies, the thrombopoietin receptor agonists, have converted ITP care. they've excessive efficacy, are nicely tolerated and ameliorate cases ' high-quality of lifestyles. An extra expertise of the underpinning pathophysiology of this criticism has helped development more recent targeted curatives. These consist of inhibitors of the neonatal Fc receptor inhibitors, Bruton tyrosine kinase and supplement pathway. Then we bandy the mechanisms underlying ITP and the new method to ITP care.

Keywords – Immune Thrombocytopenia, Immune Suppression, Thrombopoietin Receptor Agonists

I. Introduction

Autoimmune disease places a tremendous burden on the healthcare system affecting between 3- 9% of the population.(1) British Society of Immunology, spent £13bn on treating autoimmune diseases in UK. Despite advances in management, the morbidity and mortality remain high for numerous of those diseases. Primary immune thrombocytopenia is an organ-specific autoimmune disease characterized via a reduced peripheral blood platelet count.(2) Signs and symptoms encompass fatigue in addition to dry or wet purpura. Many patients have few or most specific slight signs and symptoms however intense and life-threatening bleeding may do. kindly frustratingly, certainly ITP remains an opinion of exclusion; there ought to be no sensible underpinning reason for the thrombocytopenia installation on research.(3) ITP in which there's a sensible underpinning reason is nominated secondary ITP however we won't discuss this. The decreased peripheral blood platelet count is a result of a combination of untimely platelet destruction(4) and a relative inadequacy of platelet production.(5) in addition to antibody- intermediated platelet destruction, which has been known for the reason that 1950s, 4 different mechanisms are effortlessly worried. these include T- cellular mediated apoptosis of megakaryocytes, inhibition of platelet production and T cellular destruction of platelets.(6) The underpinning pathophysiology is extra understood moment and has caused the development of latest remedies along with the TPO- RAs, syk inhibitor, Fcγ receptor(FcγR) inhibition, and other remedies.

Corresponding Author: Maged Naser

II. ITP Pathophysiology

It's been 70 ys for the reason that notorious Harrington- Hollingsworth trial become accomplished showing that plasma from instances with ITP prompted giant thrombocytopenia whilst infused into healthful volunteers.(7) It now appears that B and T cellular defects are a critical point of ITP pathophysiology and the maximum compelling evidence is that platelet autoimmunity is resulting from a failure of self tolerance mechanisms.(8,9,10) Immune effector medium in ITP. due to a breakdown in self tolerance, APC(inclusive of megakaryocytes) process and present platelet autoantigens to autoreactive T cells, which also begin a cascade of events such as stimulation of autoantibody product and cytotoxic T cell activation. Those mechanisms cause supplemental platelet destruction and megakaryocyte inhibition inside the bone marrow. further, autoantibody- opsonized platelets may additionally come below the attack of the complement cascade.

1.1 Defects in antigen providing cells

Basically all IgG responses, which includes autoimmune IgG product in ITP, are initiated by using T helper cells that fete their cognate peptide antigens in association with main histocompatibility complexes(MHC) on antigen providing cells(APC).(11,12,13) APC are an exceptional set of cells which consist of dendritic cells(DC), macrophages and in some instances, B cells. latest research have cautioned that indeed platelets and their parental cells, the megakaryocytes, can act as antigen supplying cells.(14,15,16) DCs are the most effective professional APC within the innate immunity machine(17) and numerous reviews have confirmed their impairment inITP.(13,18,19) For case, Catani etal. (18) confirmed that DCs had the capability to stimulate autoreactive T cellular proliferation upon platelet task in vitro and this turned into attributed to elevated CD86 expression on the DC surface. likewise, low figures of plasmacytoid DCs(pDCs) had been observed in cases with primary ITP and those tormented by secondary ITP associated with Helicobacter pylori infection, and those low figures extensively identified with low platelet counts.(20) It turned into cautioned that a lack of kind 1 interferon secreted via the pDCs might also play an element modulating actuated autoreactive T cells inITP.(20) perhaps greater important have been the observations of Catani et al(18) who showed that DC- related indoleamine 2,3- dioxygenase 1(IDO1) was decreased in patients with ITP and this allowed to impair the differentiation of regulatory T cells(Tregs) which contributes to the located Treg insufficiency in ITP.

As DC are the only of all APC populations, it isn't surprising that their abnormalities play a critical part in ITP T cell pathogenic mechanisms, and molecules directed at correcting DC defects can be an attractive road for ITP remedy. With respects to macrophages, it's widely known that they are the primary phagocyte liable for splenic platelet destruction in ITP. similarly, those cells, in particular during inflammation e.g. bacterial infections, can be actuated by inflammatory cytokines which include IFN- γ to over- adjust MHC class II molecules and enhance the antigen presenting functionality of the cells. this can result in a double side sword in ITP in which the macrophage no longer handiest spoil autoantibody- opsonized platelets, however also methods and gift platelet autoantigens to autoreactive T helper cells. similar as script might also make a contribution a nonstop autoantigen comments circle, which needs to be damaged with the aid of immunosuppressive treatment. Implicit mechanisms of self tolerance breakdown in ITP. Dendritic mobile abnormalities can also play a critical element in inhibiting Treg and Breg suppressive activities even as stimulating autoreactive effector mechanisms. in addition, defects in NK cells and MDSCs may additionally make contributions to autoimmune technology.

1.2 Soluble factors

Patients with ITP also have several abnormalities associated with soluble immune mediators comparable as cytokines, chemokines and supplement proteins. Within the early 1970s, one of the first observations of cytokine impairment in ITP became the immoderate in vitro made of macrophage inhibition factor (MIF) by means of lymphocytes from patients withITP.(21) This pioneering study have been one of the first descriptions of a T cell abnormality in ITP as MIF is mostly a T cell- derived element, despite the fact that other cellular sorts have now been proven to harbour this preformed cytokine.(22). latterly, several publications of other cytokine abnormalities had been suggested that have culminated in the widely universal dogma that active ITP is a manifestation of Th1 and Th17 cytokines most presumably due to a loss of Treg supression of autoimmunity.(9,10,23,24) The inverse relationship among Th1/ Th17 cytokines and diminished Treg exertion in ITP is striking and, of interest, the commonplace thing related to reversing this relationship is the boom in platelet counts(mass) in cases after treatment with a wide range of various curatives.(25) This isn't a surprising locating as platelets include excessive portions of reworking growth factor (TGF)- β, a major molecular transfer to set off Treg product.(26,27,28, 29,30,31) With appreciate to complement, the IgG autoantibodies shaped in ITP have the capability to fix complement and complement factors are set up at the

platelet surface.(32,33) both these approaches can make a contribution to platelet destruction in ITP. despite those observations, little exploration has been accomplished on serum supplement in ITP and limited statistics exist on whether or not complement conditions play a tremendous element in disease pathophysiology. In spite of this, nevertheless targeting supplement similar because the C1 esterase inhibitor sutimlimab are currently being studied inside the treatment of ITP.(34, 35)

1.3 NK & T lymphocyte dysregulation

Natural killer (NK) cells are a cytotoxic lymphocyte of the innate immune system that have rapid-rapid responses in opposition to virally- infected host cells and are actuated by way of tumour formation.(36, 37) they have a completely unique functionality to recognize and kill target cells in the absence of antibodies and/ or MHC expression which allows them to behave fast on abnormal cells. Early research advised that although NK cell numbers in the prephiral blood of cases with ITP were fairly normal, their capability to kill K562 erythroleukaemic target cells in vitro turned into significantly suppressed.(38) Ebbo et al(39) validated that NK cytotoxicity became additionally suppressed in spleen cells from cases with ITP. More currently, El- Rashedi et al(40) examined NK cells in children with ITP and concluded that adolescence ITP is associated with a growth in cytotoxic T lymphocytes, but a drop in prephiral blood NK cells. The motives for those observations are doubtful, in particular given that patients with ITP have increased levels of interferon- γ that is normally produced by using NK cells.(24,41) NK cells are known inhibitors of B cell differentiation and affinity development (42,43) and consequently, it could be that their suppressed exertion can effect autoantibody product in ITP.

Autoantibody product in cases with ITP isn't unbiased, however below the manipulate of T cellular law, become proposed via Hymes et al. (44) This early have a look at advised that a defective CD8 T cell suppression became responsible for the influence of anti-platelet autoantibodies. It also took nearly 27 years for the notion that loss of T cellular repression turned into obvious in ITP when Liu et al (9,45) confirmed that patients with ITP have imperfect and decreased numbers of CD4 T regulatory cells. Consequently, defective Tregs in ITP and this laid the inspiration that ITP is due to a loss of peripheral T cell tolerance mechanisms.(8,9) different defects in cells concerned in immune responses similarly to Treg abnormalities in ITP, numerous different myeloid and lymphoid abnormalities had been proved that probably additionally play a part in the pathogenesis of the disease. For instance, Li et al(46) elegantly proven that CD19(+) CD24(hello) CD38(hi) B regulatory cells(Bregs) are reduced in variety and defective in ITP, characterized with the aid of deficient made from the 07b031025f5f96dfa8443f843db463b6 cytokine IL- 10. This results in the inhibition of monocyte TNF- α expression, (47,48) however in addition intriguingly, when thrombopoietin(TPO) remedy expanded platelet counts inside the patients with ITP, it also accelerated Breg numbers and function, simply as observations showing increases in platelet counts following TPO treatment rescues the Treg deficiency in ITP" (49). consequently, the compromised Breg compartment causes good sized immune dysregulation in ITP and prefer Tregs, this cell population may be an efficient goal for treatment.

Alternately, in discrepancy to the low numbers of Breg in the prephiral, Aslam et al(50) set up Bregs to be significantly multiplied in the spleens of cases with ITP suggesting that peripheral reductions of Breg numbers, at the least, may be due to sequestration of these potent immunoregulatory cells. on the other hand, myeloid- deduced suppressor cells(MDSCs) have also been shown to be abnormal in patients with ITP. MDSCs are a miscellaneous population of myeloid progenitor cells which have been proven to be powerful controllers of adaptive immunity(51) having the capability to inhibit T cell proliferation with the aid of starving the cells of nutrients required.(52) Hou et al(53) verified that MSDC had been deficient in cases with active ITP and that excessive treatment dexamethasone treatment saved the MDSC numbers and restored Treg characteristic. This work shows an essential element for MDSC within the pathogenesis and corticosteroid management of ITP andTC5 similar outcomes with appreciate to MSDC numbers have been located in spleen cell cultures from ITP cases dealt with with intravenous immunoglobulin(IVIg).(54) Given the wealth of facts now recognized approximately the pathophysiology of ITP, there are numerous specific immune mechanisms that can be centred by way of treatment. specifically, lively ITP is the result of a lack of immune tolerance because of faulty Tregs and any remedial designed to raise Tregs will finally boost platelet counts in patients. it's clear, nevertheless, that further introductory and clinical exploration is needed to unfold the precise mechanisms answerable for immune dysregulation in ITP.

2. Biomarkers and IT prognosis

2.1 Discovery of Platelet Autoantibodies and analysis of Platelet Antigen

Beginning with understanding of the pathophysiology of the disease, the original pointers hired for ITP opinion were found. Given that ITP is an autoimmune disorder, it became handiest natural to check for the presence of positive autoantibodies or exploration antigenic modifications on the surface of platelets that might spark an unwarranted immune reaction. with the aid of the use of the changed monoclonal antibody immobilization of platelet antigen (WAIPA) assay, it is possible to become aware of glycoprotein(GP) unique autoantibodies, similar as GPVI, GPIb/ IX, and GPIIb/ IIIa autoantibodies, within the maturity of platelet or plasma eluates from ITP patients. these antibodies bind to the focused glycoproteins via an antigen- binding fragment(Fab), which additionally activates the mononuclear-macrophage or supplement system machine(55,56). approximately 75% of platelet autoantigens are focused within the GP Ii/ IIIa or GP Ib IX complicated of the platelet. The antigenic force in chronic ITP can be restrained, as substantiated by means of the inhibition of the listing of autoantibodies from numerous ITP patients by both any other ITP autoantibody or a monoclonal anti- GPIIb/ IIIa antibody. more than one antibodies may be produced by way of several patients (57). The accurate detection of platelet autoantibodies might help the clinical diagnosis, however their utility within the thrombocytopenia person workup is constrained by way of the low specificity and sensitivity of the presently to be had platelet autoantibody checking out. The improvement of ways for glycoprotein-particular autoantibody detection has expanded check particularity and made it applicable to diagnose ITP but now not essential depend it.

Certainly within studies using assays that are analogous, the specificity of these tests differs significantly. It's apparent from multiples researches that this modification may be reckoned for by using versions within the test characteristics, similar as variations within the glycoprotein-specific monoclonal antibodies, the glycoproteins which might be examined, the platelet numbers used in the assay, and the cut-off situations for positive and negative effects, as well as variations in the patient populations that have been subjected to the checks. it could be appropriate to similarly regularize and optimize direct autoantibody detection approaches to boost sensitivity without sacrificing specificity, but this will possibly not be enough to split the background indicators from the continuously very vulnerable specific autoantibody indicators(58). hence, improvements in autoantibody discovery technologies will enhance sensitivity to a role suitable for ITP diagnosis. In ITP, there was a reduction inside the expression of FC gamma receptors(FCGR) IIb on macrophages. The pathophysiology of ITP may be instructed through decrease expression of FCGRIIb. A new biomarker for ITP analysis can be the version in FCGRIIb(59). As a final point, serologic analyses for anti-nuclear antibodies(Analects) play relevant locations within the identification of systemic rheumatic situations. Approximately 25 – 39% of ITP topics have measurable Analects(60), despite the fact that their medical significance is not clear. it has been said that the positivity of Analects in ITP topics became related to a greater continual course and a lesser risk of growing systemic autoimmune sicknesses(61). In a take a look at, TP subjects with a positive ANA test attain a reaction rituximab administration, at the same time as their lengthy- time period outcome became destructive. therefore, a ANA test might be beneficial for prognosticating rituximab response in ITP(62). also, ANA test positivity in ITP may additionally suggest unresponsiveness to eltrombopag treatment(63).

2.2 Immature Platelet Fragment and Megakaryocyte development indicator as individual Biomarkers

An including body of exploration outlines potential biomarkers that might help an ITP diagnosis. The immature platelet Fragment (IPF) is the sort labels, that is fluently handy in cutting-edge automatic haematology analysers with fluorescence capacity. platelets, also called reticulated platelets, which have just been currently liberated from the bone marrow with the aid of megakaryocytes, represent a selected population of platelets. it's been supposed that these platelets are extra reactive than mature platelets because they comprise modest portions of RNA within the cytoplasm(64). IPF determination is a low- cost, reliable, and reliable method for reticulated platelet evaluation that has made it possible to screen for and distinguish among thrombocytopenia from numerous causes(65) IPF(%) value turned into elevated by way of the platelet matter to benefit absolutely the immature platelet count (AIPC) value, which represents the absolute number of reticulated platelets(66). IPF may be exactly detected in blood samples indeed 24 h after they've been drawn(67), maximum probable because they live longer than mature platelets. likewise, by analyzing immature platelets, consumptive thrombocytopenic process and people defined through platelet hypo-production can be fluently outstanding(68). therefore, these counts may also imply whether the motive of the thrombocytopenia is critical(forming inside the bone marrow) or supplemental(forming away)(69). The made of immature platelets doesn't appear to be impacted by means of gender(70) or age, because it keeps certainly in aged humans with dropped platelet counts(71). exclusive specifics, still, could have an effect on IPF, and whilst immune responses target platelets, their

conditions can upward thrust appreciably over reference ranges(72,73). in line with reviews, bone marrow tries to offset platelet destruction via notably including the- IPF to deal with the consumptive/ favourable manner(%). these will increase appear to be lesser in humans with continual ITP(74), and these dynamics may help stratify patients at hazard of bleeding as they sense to have an advanced IPF role(75,76).

Immature platelets are thus much like reticulocyte counts within the presence of anaemia and provide the clinician important information for treating thrombocytopenic patients. the nearest thing to real- time facts approximately the bone marrow's reaction to the aetiology producing the thrombocytopenia is exceeded with the aid of those immature platelet counts(77). In assessment to a control institution, instances with ITP had an advanced IPF value and a lower platelet count number, in keeping with a take a look at. In a trial, the IPF values were13.80% and three.00%, independently, for the ITP and manipulate organization. The location below the curve for the IPF cut-off fee with the very best sensitivity and specificity was 0.973%, and the reduce-off fee was6.3%(78). other studies have demonstrated the opportunity to apply IPF to differentiate thrombocytopenia for platelet consumption, supporting its application in research into the causes of thrombocytopenia(79). in their investigation, Serramando et al., Set up that an IPF cut- off of 11.7% had a sensitivity of 88.2% and a specificity of 91.5%(80). Their outcomes show that IPF can determine platelet healing in patients with thrombocytopenia and propose that IPF has the discriminative functionality to perceive the causes of thrombocytopenia. It has additionally been found that peculiar recommendations of ITP megakaryocyte maturation exist. The protein biomarker called tumour necrosis factor- related apoptosis- inducing ligand(trail) is a member of the TNF superfamily. Megakaryocyte development and apoptosis can both be backed with the aid of trail. It changed into shown that decreased platelet conformation in ITP become resulting from low expression of path in megakaryocytes. Megakaryocyte path expression became downregulated, as were patient path concentrations. A proposed medium through which the megakaryocyte variety will increase in vitro may be the megakaryocyte demise as a result of trail inside the plasma of ITP cases(81). A revision of megakaryocyte development signs could be a useful parameter for the assessment of bone marrow replicative dynamics.

2.3 Chemokines and ITP prognosis

Some chemokines likewise seem to envelop a generally comparative significance regarding cell development. Chemokines are small proteins that join to receptors on various leukocyte types to direct chemotactic action and the development of cells. Chemokines are grouped into the C, CC, CXC, and CX3C families in view of the moderated cysteine theme, with the CC and CXC chemokines getting the most consideration [82]. A few individuals from the CXC family, like CXCL12 and its ligand (CXCR4), add to migration, homing, multiplication, and survival of hematopoietic stem cells [83]. Wang et al. explored the megakaryocyte lineage from CFUMeg to platelets and observed that CXCR4 was communicated in these cells [84]. In their examination, flow cytometry examination of this receptor's expression revealed that CXCR4 expression increments with development and turns out to be practically uniform in the last stages in flowing platelets, displaying the best expression level in circulating platelets.

In a review, real time PCR was utilized to look at CXCR4 gene expression in ITP patients both when treatment. Normally, corticosteroids (prednisone, prednisolone, dexamethasone, or methylprednisolone) or immunoglobulins (IVG) are utilized as the first-line treatment. The patients in this study were all new cases; hence, they generally got first-line treatment for a length of 5-7 days. The statement of the CXCR4 quality showed a huge reduction in examination with the benchmark group, while its demeanor didn't change previously or after treatment [85].

In any case, the CXCR4 level is reasonable different in intense and ongoing ITP and furthermore in various phases of illness movement. Also, a few examinations play analysed the part of this chemokine receptor in different sicknesses, including foundational lupus erythematosus, HIV and haematologic malignancies, for example, intense myeloid leukemia, intense lymphoid leukemia, fundamental thrombocythemia and aplastic paleness. Despite the fact that CXCR4 is probably going to be a middle person with a few cell capabilities in various phases of development of platelets and megakaryocytes, the utilization of this biomarker should think about these information and the likelihood that a modification of the chemokine articulation might be owing to other causes. However, an alternate importance could be the examination of an alternate chemokine. A little cytokine from the CXC chemokine family, CXC chemokine ligand-13 (CXCL13), is generally delivered by optional lymphoid tissue, lymph organs, and serum follicular dendritic cells [86]. B1 cell homing, the union of normal antibodies, and body depression invulnerability all rely upon CXCL13 [87]. Moreover, it has been noticed that CXCL13 is a helpful objective for various immunological diseases and it is fundamental for the enrolment of B cells and Lymphocyte subsets in obsessive circumstances [88].

ITP patients had more significant levels of CXCL13, as indicated by research [89]. Kids with ITP announced expanded plasma CXCL13 contrasted with controls; in any case, this fixation diminished after treatment. Dexamethasone decreased CXCL13 levels in vitro in a portion and time-subordinate way. With respect to the system, it was shown that in CD4+ White blood cells, miR-125-5p emulates brought down the CXCL13 level, though a miR-125-5p inhibitor helped the CXCL13 level. MiR-125-5p was recommended to have CXCL13 as an objective quality. A decrease in CXCL13 brought about by dexamethasone was moreover forestalled by the miR-125-5p inhibitor. The miR-125-5p objective quality, CXCL13, may assume a part in the pathogenesis of ITP and furthermore act as an illness marker [90].

At long last, resistant issues and critical heterogeneity were available in ITP patients with CCR7, and it was shown that CCR7 was ensnared in the illness' turn of events. In contrast with solid controls, pretreatment ITP patients had higher CD4/CD8 proportions, lower levels of NK cells and CD4+CD25+CD127low Tregs, and lower levels of NK cells. In contrast with the backslid bunch, the recently analysed bunch showed a more noteworthy CD4/CD8 proportion and more NK cells. Treg levels were higher in the gathering encountering reduction than in the gathering encountering repeat. When contrasted with controls and the reduction bunch, the recently analysed and backslid bunches showed bigger expansions in the CD4+CCR7+, CD8+CCR7+, and CCR7+ subsets of B cells and NK cells. In contrast with the recently analysed bunch, the qualities for the CD4+CCR7+ and CD8+CCR7+ subsets in the backslid bunch were hardly higher. When contrasted with the backslid bunch, the CCR7+ subsets of CD4+ Immune system microorganisms, CD8+ Lymphocytes, NK cells, and B cells in the abatement bunch had lower levels. The reduction bunch had more elevated levels of the CD8+CCR7+ subset and lower levels of NK cells than the controls. ITP patients had a lower proportion of the CD4+CCR7+ to CDsituations 8+CCR7+ subsets than did sound controls. The CD8+CCR7+ subgroup and platelet include in ITP patients had a negative relationship [91].

2.4 BAFF and Autoreactive Cells

As our expertise of the aetiology of ITP has extended, other person guidelines had been related. The circle of relatives of tumour necrosis factor ligands member B- cell activating aspect(BAFF), also called B lymphocyte stimulator, is important for preserving right B- cell boom, homeostasis, auto-reactivity, and T- cellular costimulation(92,93). it's been verified that BAFF promotes CD19 expression and mediates the development of autoreactive B cells(94,95,96). It has been pronounced that excessive BAFF can help the demise of autoreactive B and T cells(97). in comparison to individuals in remission and controls, individualities with active disease confirmed lesser ranges of plasma BAFF and BAFF mRNA. In in vitro exams, rhBAFF promoted the survival of of CD8 and CD19 cells. these effects suggest that BAFF may also contribute to the pathogenesis of ITP through enhancing CD19 and CD8 cell survival, and enhancing platelet loss of life. The importance of BAFF expression in pediatric ITP cases changed into currently assessed by way of an observe. three groups of pediatric ITP cases were selected. Group I contained patients with acute ITP, group II cases with affected person ITP, and group III formed via healthful controls. compared to controls, BAFF expression levels vastly multiplied in ITP cases. Groups I and II, nonetheless, had authentic BAFF expression levels(98). these findings support BAFF's potential involvement within the infection and its inclusion within the person constellation.

3. Position of Interleukins in Secondary Thrombocytopenias

The fundamental reason of ITP's onset is immunological tolerance. In addition cytokines were related to ITP in recent times, according to research. The elements that could distinguish ITP from different types of thrombocytopenia and serve a particular element in the diagnosis of ITP. All immune- mediated thrombocytopenias, except for primary ITP, are categorized as secondary ITP. Numerous situations can cause secondary ITP, consisting of autoimmune conditions similar as systemic lupus erythematosus(SLE). SLE is a complex autoimmune disease this is constantly accompanied by using hematological abnormalities(99), similar as thrombocytopenia, which has been estimated to have an effect on 7 – 30% of SLE cases(100,101). It is probably challenging to discover the type of platelet clearance present in individualities with SLE in the initial ranges while there are only thrombocytopenia symptoms(102). Thrombocytopenia in SLE has a varied and complicated aetiology. Nonetheless, it is normally conceded that the pathogenesis is backed by means of improved platelet clearance because of platelet-specific autoantibodies, that's a medium analogous to ITP(103). There are eleven members of the interleukin(IL)- 1 cytokine family of protein molecules, inclusive of IL- 1(IL- 1F1), IL- 1(IL- 1F2), IL- 1 receptor antagonist(IL- 1Ra, IL- 1F3), IL- 18(IL- 1F4), IL-36Ra(IL- 1F5), IL- 36(IL- 1F6), IL- 37(IL- 1F7), and IL- 36(IL- 1F8). The pathophysiology of SLE and ITP may be instructed through aberrant variations in IL- 18 and IL-18-binding protein(IL- 18BP), in step with numerous researchs(104,105,106,107).

Likewise, current exploration suggests that IL- 1 may additionally make a contribution to the product of T- helper 17(Th17) cells, that have been installation to be mope prevalent in individualities with SLE and ITP. This shows that IL- 1 may also conceivably have a component in inflammatory pathologies and autoimmune illnesses(108,109). In a study, IL- 1 cytokines had been measured in currently diagnosed ITP patients, SLE patients with thrombocytopenia(SLE- TP), SLE cases with out thrombocytopenia(SLE- NTP), and healthy controls the usage of a multiplex cytokine assay and RT- PCR(110). In discrepancy to SLE- TP cases, SLE- NTP cases, and wholesome controls, ITP cases had considerably lower serum conditions of IL- 1, IL- 18, and IL- 36. there was a beneficial link among the platelet count and IL- 37 level in ITP cases, no matter the reality that there has been no perceptible distinction inside the serum position of IL- 37 among ITP and SLE- TP instances. these findings cautioned that blood situations of IL- 1, IL- 18, IL- 36, IL- 36 and IL- 37 should serve as ITP biomarkers.

As a result, blood situations of IL- 1, IL- 18, IL- 36, and IL- 36 can be used as biomarkers to distinguish SLE- TP cases from ITP cases(110,111). These consequences earn a few commentary. ITP and SLE- TP are both because of antibodies that assault platelets; nevertheless, it's unclear what makes them different. Differences between ITP and SLETP cases ' prephiral blood absolute lymphocyte counts and neutrophil counts in this have a look at point to distinct cellular impunity. IL- 1, IL- 18, IL- 36, and IL- 33 are intertwined within the aetiology of ITP however no longer SLE. The expression of IL- 1 mRNA between ITP cases and SLE- TP cases didn't vary extensively, that is an interesting finding. ITP and SLE- TP cases ' adjustments in IL- 1 cytokine expression at the mRNA role did not match those visible at the protein level. Therefore, it might be changed. Interleukin(IL)- 2 and interferon(IFN)- gamma ranges have been set up to be superior in the serum, while IL- 4 levels have been especially decreased. Thrombopoietin(TPO) levels have also been found to be normal, even as accelerated conditions of IL- 11 have been noted(112).

Those findings show that the Th1 kind of T helper cytokine response is linked to ITP, but the Th2 type is downregulated. Megakaryocytes are originally found in bone marrow aspirates at normal amounts, which explains why TPO product is unaltered. The expanded production of platelets in keeping with megakaryocyte may be a reflection of the rise in IL- 11. As a result, the cytokine profile and lymphocyte populations look like characteristic within the forms of thrombocytopenia and could represent a valid assist for the differential diagnosis of the various pathologies.

4.Non-coding DNA and ITP diagnosis

Numerous information revealed that further than 90% of the human genome could not be translated into proteins. Non-coding RNAs(ncRNAs), together with long non-coding(lnc) RNAs and microRNA(miRNAs), are vital inside the development of human sicknesses(113). MiRNAs are a category of ncRNAs that focus on the 3-UTR of mRNAs to control gene expression and protein translation (114,115). Former study revealed that miRNAs were dysregulated and related to the control of ITP. For instance, miRNA- 99a expression became augmented in CD4 cells(116), whilst miRNA-182-5p and miRNA183- 5p expression turned into augmented in ITP. likewise, in ITP, TGFB1 and IL18 had been downregulated and inhibited by miRNA130A(117). MiRNA409-3p turned into additionally stated to be dropped in ITP samples on the equal time(118). additionally, lncRNAs have been linked to autoimmune illnesses and their signs and symptoms. Wang etal. observed that the expression of the lncRNA TMEVPG1 turned into lower in ITP subjects with respect to samples from wholesome control subjects(119). In a different study, 1177 and 632 lncRNAs had been shown to be appreciably over- or down- regulated in ITP cases, as compared to regular samples(120). In a trial that examined several open- get entry to datasets, which includes GSE43177 and GSE43178, it was determined that ITP cases had 468 upregulated mRNAs, 272 downregulated mRNAs, 134 upregulated lncRNAs, 23 downregulated lncRNAs, 29 upregulated miRNAs, and 39 downregulated miRNAs. After that, authors created networks in ITP for the co-expression of lncRNA, miRNA- mRNA, and protein- protein members of the family. A bioinformatics investigation revealed that those genes managed numerous biological functions in ITP, inclusive of translation, cell- cell adhesion, ubiquitin- mediated proteasome degradation, and mRNA nonsense-intermediated decay. As an end result, cases with ITP seem to have a specific profile of miRNAs, which can be helpful for a greater accurate opinion. nonetheless, it's really worth noting that utmost of the outcomes reported haven't been reproduced, which may be due to specific blood resources, or special populace sizes, in addition to the use of different RNA isolation and identification processes. Therefore, standardized discovery schemes are demanded within the coming instances, comprising extra sensitive miRNA discovery approaches and quantitative evaluation models, whilst an agreement at the clinical importance of a many targets is essential for their use in clinical practice(121).

5.Gut Microbiota and ITP

Numerous autoimmune illnesses present an altered gut microbiota, which became indeed as one in every of their aetiologies. The human intestine is home to similarly than one thousand distinctive sorts of micro organism, which might be critical to each health and sickness(122,123,124,125,126). The gut is in which over 60% of human immunity is controlled. Mice raised in a germ-free environment have a susceptible immune system, and their immune cells significantly demenish. latest exploration has revealed a connection among changes in the gut microbiota's composition and functionality and illness symptoms, severity, and treatment response(127). The remedial benefit of probiotic supplementation or fecal microbiota transplantation in individualities with autoimmune diseases is significant(128). also, several extra-intestinal autoimmune situations and immunological sicknesses, comparable as rheumatoid arthritis, type 1 diabetes, multiple sclerosis, and systemic lupus erythematosus, were linked to gut microbiota (129). The gut microbiome might also affect ITP. In a look at, the metabolite biographies and gut microbial community were tested the usage of feces from adult primary ITP cases who have been untreated and healthful controls (HCs)(130).Consistent with the findings, ITP cases have decrease levels of Bacteroids and advanced levels of the fecal micro organism Blautia, Streptococcus, and Lactobacillus. in particular, fecal metabolites similar as glycerophospholipids and adipose acids are amended and intensively relate with discrepant gut microbiota. Weissella and Streptococcus anginosus, Cer(t18:0/ 16:0), Cer(d181/ 1/17:0), and 13- hydroxyoctadecanoic acid mixtures may also be powerful individual pointers for ITP(130). In end, in comparison to HCs, ITP cases witness dysbiosis of the gut microbiota and metabolome. several gut chemical substances and micro organism modified through ITP can function ITP biomarkers.

6.Complement Activation Biomarkers

An essential medium of platelet destruction is complement activation due to anti- GPIIb/ IIIa(131,132,133,134,135,136,137,138). The complement system, a significantly blood- born protein cascade, has its evolutionary roots in homeostasis and innate immune protection(139). ITP has been related to shady levels of platelet- associated complement (140,141,142,143). Nevertheless, there have only been a few reports of studies on the regulation and specificity of complement activation(144). In ITP cases with anti-GPIIb/ IIIa antibodies, complement activation and bettered complement activation capacity(CAC) have been set up each in vivo and in vitro research. Cases in this group confirmed dropped plasma levels of 2- GPI, which turned into negatively related with C5b- 9 deposit. Approximate physiological quantities of 2- GPI suppressed C5b- 9 product in a dose-dependent way(145). Inhibition of C3a product by β2- GPI and the presence of β2- GPI/ C3 complexes in plasma advised a control at the function of the C3 convertase. also, c- Jun N-terminal kinase(JNK) phosphorylation levels have been downregulated by means of 2- GPI, as turned into the cleavage of the BH3 interacting domain death agonist(Bid), which brought about platelet lysis. those statistics advise a completely unique dating between dropped tube 2- GPI conditions and elevated supplement activation, suggesting that 2- GPI can be beneficial as a biomarker. ultimately, anti-complement 1q antibody(anti-C1q), complement factor H(CFH), complement fractions Bb(CFBb), stromal- derived factor- 1(SDF1, additionally called CXCL12), and IL21 plasma levels had been tested through Sahip et al. to see if there was any correlation among them and the medical characteristics of ITP. Cases with ITP had decrease levels of CFH and CFBb and greater levels of anti-C1q compared to controls. The differences in and CFH levels following remedy assist the idea that the complement system performs a role within the pathogenesis of ITP(146).

Table 1. Possible biomarkers in ITP diagnosis.

Diagnostic Value	Biomarker	Significance	Refs.
	GPVI, GPIb/IX, and GPIIb/IIIa autoantibodies	Expression of autoimmune disease	[55,56,57,58]
	Reduction in the expression of FC gamma receptors (FCGR) IIb in macrophages	Correlation with H. Pylori infection	[59]
	Immature platelet fraction	Ability to distinguish between	[69,74,75,76,77,78,79,80]

	(IPF)	thrombocytopenia due to consumptive processes platelet hypoproduction	
	Expression of TRAIL in megakaryocytes	Megakaryocyte maturation index	[81]
	CXCR4	Maturation index	[85]
	CXCL13	Effect on immune response	[89,90]
	BAFF	Effect on the development of autoreactive B cells	[98]
	IL-1, IL-18, IL-36, IL-36, and IL-33	Ability to distinguish between primary and secondary thrombocytopenia	[110]
	IL-2, IL-11, IFN	Markers of Th1 type of T helper cytokine response	[112]
	miRNA-99, miRNA-182-5p, miRNA183-5p, miRNA130A, miRNA409-3p expression	Epigenetic control of cell-cell adhesion, ubiquitin-mediated proteasome degradation, and mRNA nonsense-mediated decay	[116,117,118]
	lncRNA TMEVPG1	Epigenetic control	[119,120,121,122]
	Gut microbiome	Effects on immune response	[130]
	Complement	Complement activation caused by anti-GPIIb/IIIa	[144,145]

7.Transcriptome evaluation

Research that makes use of genetic evaluation to discover ITP cases is extraordinarily encouraging. The topmost number of platelet transcriptome samples had been gathered in a current observe. Using RNA sequencing(RNA- seq) transcriptomes, a thorough process of factor selection, engineering, and stacking category become carried out to locate the ITP biomarkers(147). The final ITP factor discovery version become skilled the usage of the 40 found biomarkers, and its usual accuracy was 0.974. The biomarkers discovered that a number of transcribed factors, comparable as protein- coding genes, long intergenic non-coding RNA genes, and pseudogenes with apparent transcription, may be related to the release of ITP. The handed ITP discovery version also can be used to diagnose ITP. Multitudinous biomarkers displayed expression patterns that have been in large part tissue-specific; for illustration, the genes DNAH7 and AANAT had been only explosively expressed inside the testis, whereas the gene KLHDC8A became only largely expressed within the ovary. DNAH10OS, NORAD, MT- ATP8, HNRNPUL2, MT- RNR2, and MT- CO2 have been some of the genes with high expression in various brain regions, although the majority of the 40 biomarkers had pretty low expression inside the overall blood. it's important to look at the molecular techniques of ITP using platelet cells because the information found out that the abnormal expressions of these tissue-specific expressed genes might also have contributed to ITP's development and progression when combined with their ITP-specific expression patterns.

8.Prognostic Biomarkers Refractory ITP

Indeed after coming into numerous traces of single- agent modifications, a few ITP cases hold to now not reply to conventional remedies, in spite of therapeutical improvements. Refractory ITP is connected to an extreme decline in high-quality of life and extraordinarily challenging remedial care. To make matters certainly extra sensitive, clinicians ' experience in is pivotal to properly treating refractory ITP because the diagnosis remains grounded on exclusion(148). Approximately 10% of ITP cases come resistive to treatment within a time, in step with Psaila etal. In these situations, the lack of a scientific reaction calls into extreme doubt the diagnosis of ITP(149) and need to prompt a thorough clinical and laboratory work- up(150) to rule out different underpinning illnesses, in particular myelodysplastic syndromes, drug- induced on thrombocytopenia, inherited thrombocytopenia, and bone marrow failure syndromes. also, type IIB von Willebrand disease and pseudo-thrombocytopenia ought to be ruled out. Refractory ITP has been described in numerous methods over the years. Refractory ITP used to commonly be rested at the absence of reaction or relapse following splenectomy. More specifically, failure to reach a platelet count of 30,000/ L and a doubling of baseline platelet counts had been utilized by Rodeghiero et al., to determine response(151). The 2010 ASH guidelines(152) affirmed and supported this description of refractory ITP. nonetheless, splenectomy is not an option for a sizeable percentage threat of ITP cases, specially people who are elderly or with other critical co-morbidities. additionally, humans may be reluctant to have a splenectomy and decline the remedy. also, its pediatric indication is poor (153). Cuker etal. expand the description of refractory ITP to encompass cases who need treatment however are unable or unwilling to have a splenectomy(154), even as an entire loss of reaction to one or further single- agent remedies, similar as rituximab and TPO- RA, turned into the description of refractory ITP in 2020(66). shortly later, Miltiadous et al., defined "refractory" cases as those whose platelet counts don't reply to, in addition than two treatments, and whose platelet counts are extremely low and are accompanied by haemorrhage(155). as a result, it is clear how important it is to have correct indicators that can study how the disease will progress. Insidious onset, a higher platelet be counted at presentation, girl gender, elderly age at presentation, a loss of preceding infection or vaccination, positivity for anti-nuclear antibodies(ANA), and an incapability to respond to a single treatment of intravenous human immunoglobulins are all allowed to be predictors of the chronic course of the disease.

9. Inheritable Traits in Refractory ITP Patients

In line with some outcomes, children with chronic ITP have a robust circle of relatives records of the condition(156). additionally, there may be evidence that ITP is inherited, with some immune-affiliated genes maybe gambling a role (157). The clinical characteristics and genetics of chronic refractory immune thrombocytopenia(C/ RITP) in infants, in addition to their significance in treatment refractoriness have, nonetheless, entered usually little exploration interest. In a study, children with C/ RITP who had immune-associated gene mutations were examined for clinical signs and genetic traits(158). Children in the mutant group had more intense hemorrhages, similarly aberrant immunological signs, and extra levels of SLE biomarker expression. The mutant group's peripheral T and B lymphocyte counts dramatically multiplied. TNFRSF13B, CARD11, CBL, and RAG2 are four genes related to primary immunodeficiencies which are mutated in17.6% of cases, even as 23 other genes had variants in82.4% of cases that were of unknown importance(158). The mutant group's expanded risk of numerous aberrant immunological phenotypes might be a sign of a heritable propensity for immunodeficiencies. Immune issues manifested ahead within the mutation group of cases. Theoretically, this implies that they endure similarly frequent immunosuppressive treatment and the utility of alternate- line curatives, and that the prognostic for those kids is worse. The inflammasome complex was subordinated to a separate genomic investigation. The nicely- studied inflammasome NLRP3(NOD- suchlike receptor pyrin sphere- containing protein 3) is an element of the innate immune system that reacts to cellular stress with the aid of liberating the proinflammatory cytokines IL- 1 and IL- 18. several inflammatory and autoimmune illnesses, which include diabetes, obesity, and atherosclerosis, are brought about by means of the NLRP3 inflammasome(159,160). ITP cases ' gene expression and polymorphisms for the NLRP3 inflammasome had been examined using RT- PCR(161). By using the usage of flow cytometry, T helper cells and apoptosis of prephiral blood mononuclear cell (PBMC) from ITP cases have been examined. The NF- B- 94ins/ del ATTG genotype changed into installation to contribute to ITP immunity, in line with the results. also, ITP cases with the WW genotype or WD genotype had lower platelet counts than ITP cases with the DD genotype of NF- B- 94ins/ del ATTG. ITP cases with the WW or WD genotype confirmed advanced mRNA expression than people with the DD genotype when in comparison to controls for NF- B gene expression. analogous to this, the WW genotype additionally showed enhanced NLRP3 mRNA expression. within the organization that wasn't stimulated, there was no perceptible exchange in the percentage of Th17 cells for the genotypes WW, WD, and DD(WW WD DD), despite the fact that there has been a substantial gene dosage effect. In ITP

cases, activation of the NLRP3 inflammasome may additionally upregulate Th17(161). In summary, the NF- B- 94ins/ del ATTG genotype may be new biomarker and possible goal for ITP.

Table 2. Recent treatments designed for primary ITP.

Drug	Description	Mechanism of action
Romiplostim [68, 69, 70, 71]	Peptibody TPO-RA	Stimulates the JAK-STAT pathway. Megakaryocyte proliferation, maturation and platelet production
Eltrombopag [72,73]	Small molecule TPO-RA	Stimulates the JAK-STAT pathway. Megakaryocyte proliferation, maturation and platelet production
Avatrombopag [74]	Small molecule TPO-RA	Stimulates the JAK-STAT pathway. Megakaryocyte proliferation, maturation and platelet production
Fostamatinib[81,82]	syk inhibitor	Decreases antibody-dependent phagocytosis of platelets
Efgartigimod[84]	Anti-FcRn	Decreases the half-life of IgG, reduces plasma IgG both normal and pathogenic
Rozanolixizumab[90]	Anti-FcRn	Decreases the half-life of IgG, reduces plasma IgG both normal and pathogenic
Rilzabrutinib[86,92]	BTKI	Inhibits Fcγ signal transduction, decreases platelet phagocytosis and autoantibody production
Sutimlimab[35]	Anti-C1s	Decreases complement-dependent cytotoxicity thereby reducing platelet destruction

Abbreviations used: TPO-RA, thrombopoietin receptor agonist; FcRn, neonatal Fc receptor; JAK, Janus kinase; STAT, signal transducer and activator of transcription; BTKI, Bruton kinase inhibitor

III. Models of Treatment

Numerous of the treatments used in autoimmune disease achieve many remissions. The focus for numerous autoimmune conditions has shifted towards improving symptoms and health- related quality of life. The same is true for ITP where quality of life has been recognised as a major treatment goal for this disease.(3) The treatment models in current medical practice include the infectious disease model, oncologic disease model, metabolic disease model, and transplant rejection model. Over numerous decades, ITP has been managed using the transplant rejection model in which supression of the immune system has been used to meliorate the disease symptoms. It's clear from numerous published studies, and the recent I- Want study, (162) that this model infrequently induces remissions and has serious adverse effects on morbidity or mortality, performing in an overall poor quality of life for cases with ITP. Given that ITP is a “benign” disease, it's disappointing that treatments offer many benefits to cases whilst, at the same time, poorly affecting their health- related quality of life. Shift in emphasis down from immune supression Over many times there has been a gradational shift down from immune supression as a means of treating ITP. The recent COVID- 19 epidemic has made immune supression veritably unattractive as a modality of treatment since our focus has been on minimising patient threat from (COVID-19) (163) The TPO- RAs have filled this gap and in England and Wales, as well as other homes(Interim Clinical Commissioning Policy, NHS(E) (30), TPO- RAs are being used first line(off- label) in order to avoid the use of immune supression. This is a major paradigm shift for the operation of ITP. Attempts to alter the standard first line treatment of ITP have included the addition of mycophenolate to corticosteroids upfront for newly- diagnosed adults.(164) still, although there were smaller treatment failures in the mycophenolate arm, the quality- of- life was lower in this group. For this

reason, in addition to the avoidance of immune supression during the current epidemic, many cases have actually entered mycophenolate upfront.

1.Thrombopoietin(TPO) mimetic agents

In order to move away from immune supression, the first- generation TPO- mimetic medicines were developed in the 1990s including recombinant human TPO(rHu- TPO) and recombinant human megakaryocyte growth and development factor(rHu-MGDF).(165) By stimulating the TPO receptor these agents raised the cases ' platelet counts. still, although these TPO mimetics had good efficacy in ITP, antibodies were generated against the medicines in some cases.(166) Because the TPO mimetics were grounded on native endogenous human TPO, the antibodies against medicines were cross-reactive with native TPO performing in profound thrombocytopenia. Development of the first generation TPO mimetics was thus abandoned. Over the last 20 years there has been significant medicine development for ITP, beginning with the alternate generation thrombopoietin receptor agonists(TPO- RAs).(167, 168) This generation of TPO- RAs bears no resemblance to native thrombopoietin and thus any antibodies directed against drug shouldn't cross-react with the case's native thrombopoietin. Romiplostim is a large peptibody molecule which binds to the same point as native TPO on the extracellular portion of the TPO receptor(169, 170, 171, 172). Eltrombopag is a small hydrazone molecule that binds to the transmembrane portion of the TPO receptor (173,174). Both drugs were launched in 2008 and have been used with great success in primary immune thrombocytopenia as alternate- line agents. Their efficacy is high at around 80%(167) More lately, another small molecule TPO receptor agonist has been developed, videlicet avatrombopag.(175) This molecule binds to the same point as eltrombopag and stimulates the same pathway performing in megakaryocyte proliferation and platelet product. All three approved TPO- RAs bind to the TPO receptor and stimulate the same pathway. These new TPO mimetics are well permitted by cases and have avoided numerous cases being exposed to immune supression or splenectomy.(168) Although the TPO- RAs were regarded largely as "palliative" remedy(effective when the case was taking the TPO- RA) around one third of cases on TPO- RAs are suitable to be weaned sluggishly off the TPO- RA and maintain a safe or normal platelet count off all treatment. This is observed indeed in heavily- pretreated cases.(176, 177, 178, 179,180) Although further work needs to be carried out to determine why these cases are in a treatment-free "remission" it's possible that immune tolerance has been restored. The TPO- RAs appear to have exertion at the stem cell level, as demonstrated with the use of eltrombopag for the treatment of severe a plastic anaemia, restoring haemoglobin levels and white cell counts.(181)

The TPO- RAs have hence dramatically changed the ITP management landscape. Smaller cases endure immune supression which, at some point of an epidemic, is profitable. still, the TPO- RAs are not effective in all patients a few cases can not tolerate them or there can be contraindications to their use. Clearly, different remedy classes are wanted for those cases with a view to maintain a secure platelet be counted. Inhibition of FcγR platelet destruction syk inhibition some other new agent for ITP is fostamatinib, a small molecule syk inhibitor. This oral agent acts by way of inhibiting syk and prevents platelet breakdown by means of interfering with FcγR- intermediated destruction of opsonised platelets (182,183). Published studies have verified a response rate of for 43% in cases who were preliminarily closely pretreated. The long lasting response rate become reported at18%(184) This rate can be advanced if fostamatinib is used earlier. aside impact mentioned within the research consist of hypertension in 28%, and diarrhoea in 31% of the cases, those damaging occasions were commonly slight to moderate. Simplified schema of ITP pathogenesis displaying the sites of motion of recent curatives for ITP. Stimulatory drugs are in green and inhibitory agents are proven in red. BTKIs, Bruton tyrosine kinase inhibitors; CTLA4- Ig, Cytotoxic T Lymphocyte Antigen 4 immunoglobulin G1 fusion protein;Anti-BLys, B lymphocyte stimulator; BAFF, B cell activating factor. So, currently there are new authorised classes of treatment for ITP, Namely the TPO- RAs and a syk inhibitor. however yet further classes of treatment are in superior levels of clinical development which includes medicines active against the neonatal Fc receptor(anti-FcRn), (184,185,186) Bruton tyrosine kinase inhibitors(187) and complement inhibitors.(188, 189)

IV. Remedies in Medical Improvement

1.Anti-FcRn

The neonatal Fc receptor modulates the half of- life of IgG and albumin. It does this by way of binding to IgG and releasing it from endothelial endosomes. as well as recuperating normal IgG, the FcRn additionally recycles pathologic IgG.(190) blocking the FcRn reasons IgG breakdown within the endosomes.(185) two molecules are currently in advanced phase medical development rozanolixizumab(UCB) (191) and efgartigimod(argenx) (185). In phase 2 research, each efgartigimod and

rozanolixizumab have been well approved and responses of 38%(efgartigimod) and 50%(rozanolixizumab) had been seen.(185), phase 3 studies of each dealers are ongoing. statistics therefore some distance might appear to indicate that even though the IgG levels fall this doesn't seem to growth the chance of infection. Bruton tyrosine kinase inhibitors(BTKIs) Bruton tyrosine kinase, like syk, is concerned in Fcγ signalling and is another implicit target for ITP treatment. BTK is necessary for B cellular improvement, feature and antibody product. Several BTKIs had been developed for conditions comparable as continual lymphocytic leukaemia.(192) still, BTKIs were said to inhibit platelet aggregation which may additionally have an effect on bleeding, that's a difficulty in ITP. despite the fact that this turned into reported with ibrutinib it isn't always the case with rilzabrutinib.(187) outcomes from a latest phase 2 observe of rilzabrutinib in person instances with regressed or refractory ITP were published.(192) fifty nine adults, who had at least one preceding response to treatment and a platelet be counted ≤ 30 × 109/ L, had been given oral rilzabrutinib at 200 or 400 mg day by day or 300 or four hundred mg doubly every day. The response charge changed into seen in the four hundred mg doubly diurnal organization. Of 44 cases on this treatment 39 completed the number one endpoint(two or further platelet counts ≥ 50 × 109/ L without the usage of rescue remedy). Of the 33 cases who finished the have a look at for similarly than 12 weeks, 17 of those(52%) responded. Of the responders half of these(50%) executed a platelet matter ≥ 30 × 109/ L by day 8. Rilzabrutinib changed into well permitted with adverse events of Grade 1 or 2 only.

2.The complement system

Complement is assumed to be involved inside the pathogenesis of ITP for some cases. nonetheless, the contribution made by means of complement to ITP isn't effortlessly understood. Early phase studies with sutimlimab, a monoclonal IgG C1s inhibtor, had been conducted. The cases dealt with were adults with ITP for> 1 year and an inadequate reaction to ≥ 2 previous treatments. A 12 cases had been dealt with of which 42% responded(platelet count ≥ 50 × 109/ L). 4 cases(33%) performed a platelet count of ≥ 50 × 109/ L for ≥ 70% of their study visits. One 1/3 of cases responded in days or less. No remedy- related unfavourable events had been noted (35). another complement inhibitor, iptacopan, a selective factor B inhibitor, is presently undergoing phase 2 medical trials in ITP.

V. Conclusion

ITP has a complicated and ill-defined pathophysiology. Basic science and the want to keep away from the much less positive immune suppressants, has led to the improvement of new greater centered redress for ITP, beginning with the 2d technology TPO-RAs and now encompass syk inhibition with different instructions of remedy in medical development. The introduction of these novel remedies has allowed us to use much less immune suppression in ITP management. Over the remaining decade there has been a shift away from immune suppression for the remedy of ITP. However, the COVID-19 pandemic has forced our hand in dashing up this cross in the direction of much less immune suppressive treatments. As an end result of this, the patients' quality-of-life has increased for the reason that capsules like TPO receptor agonists have excessive efficacy and are nicely tolerated. Once the tablets present process improvement are authorized it is probable that there will be an awful lot decreased reliance on the older empirical immune suppressive therapies. These new pills additionally show up to provide sufferers a good deal greater threat of a treatment-free sustained response than with the older immune suppressants. Some of these "remissions" can also be therapies however we want lots longer follow-up of the patients.

Conflict of Interest

All authors declare no conflicts of interest.

Author Contribution

Authors have equally participated and shared every item of the work.

References

[1]-Hayter, Scott M., and Matthew C. Cook. "Updated assessment of the prevalence, spectrum and case definition of autoimmune disease." *Autoimmunity reviews* 11.10 (2012): 754-765.

[2]-Cines, Douglas B., and Victor S. Blanchette. "Immune thrombocytopenic purpura." *New England Journal of Medicine* 346.13 (2002): 995-1008.

[3]-Provan, Drew, et al. "Updated international consensus report on the investigation and management of primary immune thrombocytopenia." *Blood advances* 3.22 (2019): 3780-3817.

[4]-Harrington, William J., et al. "Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura." *The Journal of laboratory and clinical medicine* 38.1 (1951): 1-10.

[5]-Gernsheimer, Terry, et al. "Mechanisms of response to treatment in autoimmune thrombocytopenic purpura." *New England Journal of Medicine* 320.15 (1989): 974-980.

[6]-Olsson, Bob, et al. "T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura." *Nature medicine* 9.9 (2003): 1123-1124.

[7]-Semple, John W., and John Freedman. "Abnormal cellular immune mechanisms associated with autoimmune thrombocytopenia." *Transfusion Medicine Reviews* 9.4 (1995): 327-338.

[8]-Semple, John W., et al. "An update on the pathophysiology of immune thrombocytopenia." *Current opinion in hematology* 27.6 (2020): 423-429.

[9]-Audia, Sylvain, et al. "Immune thrombocytopenia: recent advances in pathogenesis and treatments." *Hemasphere* 5.6 (2021): e574.

[10]-Swinkels, Maurice, et al. "Emerging concepts in immune thrombocytopenia." *Frontiers in immunology* 9 (2018): 880.

[11]-Morante-Palacios, Octavio, et al. "Tolerogenic dendritic cells in autoimmunity and inflammatory diseases." *Trends in immunology* 42.1 (2021): 59-75.

[12]-Kissel, Karin, et al. "Human platelets target dendritic cell differentiation and production of proinflammatory cytokines." *Transfusion* 46.5 (2006): 818-827.

[13]-Catani, Lucia, et al. "Dendritic cells of immune thrombocytopenic purpura (ITP) show increased capacity to present apoptotic platelets to T lymphocytes." *Experimental hematology* 34.7 (2006): 879-887.

[14]-Chapman, Lesley M., et al. "Platelets present antigen in the context of MHC class I." *The Journal of Immunology* 189.2 (2012): 916-923.

[15]-Zufferey, Anne, et al. "Mature murine megakaryocytes present antigen-MHC class I molecules to T cells and transfer them to platelets." *Blood advances* 1.20 (2017): 1773-1785.

[16]-Marcoux, Genevieve, et al. "Platelet EVs contain an active proteasome involved in protein processing for antigen presentation via MHC-I molecules." *Blood, The Journal of the American Society of Hematology* 138.25 (2021): 2607-2620.

[17]-Zanna, Mohammed Yusuf, et al. "Review of dendritic cells, their role in clinical immunology, and distribution in various animal species." *International journal of molecular sciences* 22.15 (2021): 8044.

[18]-Catani, Lucia, et al. "Decreased expression of indoleamine 2, 3-dioxygenase 1 in dendritic cells contributes to impaired regulatory T cell development in immune thrombocytopenia." *Annals of hematology* 92 (2013): 67-78.

[19]-Xu, Shu-qian, et al. "Decreased indoleamine 2, 3-dioxygenase expression in dendritic cells and role of indoleamine 2, 3-dioxygenase-expressing dendritic cells in immune thrombocytopenia." *Annals of hematology* 91 (2012): 1623-1631.

[20]-Saito, Akio, et al. "Circulating plasmacytoid dendritic cells in patients with primary and Helicobacter pylori-associated immune thrombocytopenia." *European journal of haematology* 88.4 (2012): 340-349.

[21]-Clancy, Robert. "Cellular immunity to autologous platelets and serum-blocking factors in idiopathic thrombocytopenic purpura." *The Lancet* 299.7740 (1972): 6-9.

[22]-Calandra, Thierry, and Thierry Roger. "Macrophage migration inhibitory factor: a regulator of innate immunity." *Nature reviews immunology* 3.10 (2003): 791-800.

[23]-Zufferey, Anne, Rick Kapur, and John W. Semple. "Pathogenesis and therapeutic mechanisms in immune thrombocytopenia (ITP)." *Journal of clinical medicine* 6.2 (2017): 16.

[24]-Semple, John W., et al. "Differences in serum cytokine levels in acute and chronic autoimmune thrombocytopenic purpura: relationship to platelet phenotype and anti-platelet T-cell reactivity." (1996): 4245-4254.

[25]-Semple, John W., and Rick Kapur. "Platelet immunology from the inside out." *ISBT Science Series* 15.3 (2020): 315-319.

[26]-Karolczak, Kamil, and Cezary Watala. "Blood platelets as an important but underrated circulating source of TGFβ." *International journal of molecular sciences* 22.9 (2021): 4492.

[27]-Wang, Jiaan-Der, et al. "Reduced expression of transforming growth factor-β1 and correlated elevation of interleukin-17 and interferon-γ in pediatric patients with chronic primary immune thrombocytopenia (ITP)." *Pediatric blood & cancer* 57.4 (2011): 636-640.

[28]-Andersson, Per-Ola, Anna Olsson, and Hans Wadenvik. "Reduced transforming growth factor-β1 production by mononuclear cells from patients with active chronic idiopathic thrombocytopenic purpura." *British journal of haematology* 116.4 (2002): 862-867.

[29]-Andersson, P. O., et al. "A transforming growth factor-β1-mediated bystander immune suppression could be associated with remission of chronic idiopathic thrombocytopenic purpura." *Annals of Hematology* 79 (2000): 507-513.

[30]-Panitsas, Fotios P., et al. "Adult chronic idiopathic thrombocytopenic purpura (ITP) is the manifestation of a type-1 polarized immune response." *Blood* 103.7 (2004): 2645-2647.

[31]-Roncarolo, Maria Grazia, et al. "The biology of T regulatory type 1 cells and their therapeutic application in immune-mediated diseases." *Immunity* 49.6 (2018): 1004-1019.

[32]-Najaoui, Abderrahim, et al. "Autoantibody-mediated complement activation on platelets is a common finding in patients with immune thrombocytopenic purpura (ITP)." *European journal of haematology* 88.2 (2012): 167-174.

[33]-Kurata, Y., et al. "Platelet-associated complement in chronic ITP." *British journal of haematology* 60.4 (1985): 723-733.

[34]-Cheloff, Abraham Z., David J. Kuter, and Hanny Al-Samkari. "Serum complement levels in immune thrombocytopenia: characterization and relation to clinical features." *Research and Practice in Thrombosis and Haemostasis* 4.5 (2020): 807-812.

[35]-Broome, Catherine M., et al. "Long-term safety and efficacy of sutimlimab in patients with chronic immune thrombocytopenia." *Blood* 136 (2020): 14-15.

[36]-Pross, H. F., and Ml Jondal. "Cytotoxic lymphocytes from normal donors. A functional marker of human non-T lymphocytes." *Clinical and experimental immunology* 21.2 (1975): 226.

[37]-Kiessling, R., et al. "„Natural" killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell." *European journal of immunology* 5.2 (1975): 117-121.

[38]-Semple, John W., Suzanne Bruce, and John Freedman. "Suppressed natural killer cell activity in patients with chronic autoimmune thrombocytopenic purpura." *American journal of hematology* 37.4 (1991): 258-262.

[39]-Ebbo, M., et al. "NK cell compartment in the peripheral blood and spleen in adult patients with primary immune thrombocytopenia." *Clinical Immunology* 177 (2017): 18-28.

[40]-El-Rashedi, Farida Hussein, et al. "Study of CD4+, CD8+, and natural killer cells (CD16+, CD56+) in children with immune thrombocytopenic purpura." *Hematology/oncology and stem cell therapy* 10.1 (2017): 8-14.

[41]-Paolini, Rossella, et al. "NK cells and interferons." *Cytokine & growth factor reviews* 26.2 (2015): 113-120.

[42]-Cook, Kevin D., Hannah C. Kline, and Jason K. Whitmire. "NK cells inhibit humoral immunity by reducing the abundance of CD4+ T follicular helper cells during a chronic virus infection." *Journal of Leucocyte Biology* 98.2 (2015): 153-162.

[43]-Rydyznski, Carolyn E., et al. "Affinity maturation is impaired by natural killer cell suppression of germinal centers." *Cell reports* 24.13 (2018): 3367-3373.

[44]-Hymes, Kenneth B., and Simon Karpatkin. "In vitro suppressor T lymphocyte dysfunction in autoimmune thrombocytopenic purpura associated with a complement-fixing antibody." *British journal of haematology* 74.3 (1990): 330-335.

[45]-Liu, Bin, et al. "Abnormality of CD4+ CD25+ regulatory T cells in idiopathic thrombocytopenic purpura." *European journal of haematology* 78.2 (2007): 139-143.

[46]-Li, Xiaojuan, et al. "Defective regulatory B-cell compartment in patients with immune thrombocytopenia." *Blood, The Journal of the American Society of Hematology* 120.16 (2012): 3318-3325.

[47]-Denys, Agnes, et al. "Evidence for a dual mechanism for IL-10 suppression of TNF-α production that does not involve inhibition of p38 mitogen-activated protein kinase or NF-κB in primary human macrophages." *The Journal of Immunology* 168.10 (2002): 4837-4845.

[48]-Armstrong, Lynne, Nicola Jordan, and Ann Millar. "Interleukin 10 (IL-10) regulation of tumour necrosis factor alpha (TNF-alpha) from human alveolar macrophages and peripheral blood monocytes." *Thorax* 51.2 (1996): 143.

[49]-Bao, Weili, et al. "Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents." *Blood, The Journal of the American Society of Hematology* 116.22 (2010): 4639-4645.

[50]-Aslam, Rukhsana, et al. "Splenic lymphocyte subtypes in immune thrombocytopenia: increased presence of a subtype of B-regulatory cells." *British journal of haematology* 173.1 (2016): 159-160.

[51]-Gabrilovich, Dmitry I., and Srinivas Nagaraj. "Myeloid-derived suppressor cells as regulators of the immune system." *Nature reviews immunology* 9.3 (2009): 162-174.

[52]-Highfill, Steven L., et al. "Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1–dependent mechanism that is up-regulated by interleukin-13." *Blood, The Journal of the American Society of Hematology* 116.25 (2010): 5738-5747.

[53]-Hou, Yu, et al. "High-dose dexamethasone corrects impaired myeloid-derived suppressor cell function via Ets1 in immune thrombocytopenia." *Blood, The Journal of the American Society of Hematology* 127.12 (2016): 1587-1597.

[54]-Aslam, Rukhsana, et al. "Intravenous immunoglobulin treatment of spleen cells from patients with immune thrombocytopenia significantly increases the percentage of myeloid-derived suppressor cells." *British journal of haematology* 181.2 (2018): 262-264.

[55]-Hou, M., et al. "Antibodies against platelet GPIb/IX, GPIIb/IIIa, and other platelet antigens in chronic idiopathic thrombocytopenic purpura." *European journal of haematology* 55.5 (1995): 307-314.

[56]-McMillan, Robert. "Antiplatelet antibodies in chronic immune thrombocytopenia and their role in platelet destruction and defective platelet production." *Hematology/Oncology Clinics* 23.6 (2009): 1163-1175.

[57]-Yu, Lingjia, et al. "Biomarkers for immune thrombocytopenia." *Biomarker Research* 3 (2015): 1-4.

[58]-Porcelijn, Leendert, et al. "Evolution and utility of antiplatelet autoantibody testing in patients with immune thrombocytopenia." *Transfusion Medicine Reviews* 34.4 (2020): 258-269.

[59]-Wu, Zhong, et al. "Low expression of FCGRIIB in macrophages of immune thrombocytopenia-affected individuals." *International journal of hematology* 96 (2012): 588-593.

[60]-Moulis, Guillaume, et al. "Newly diagnosed immune thrombocytopenia adults: clinical epidemiology, exposure to treatments, and evolution. Results of the CARMEN multicenter prospective cohort." *American journal of hematology* 92.6 (2017): 493-500.

[61]-Mahévas, Matthieu, et al. "Efficacy and safety of rituximab given at 1,000 mg on days 1 and 15 compared to the standard regimen to treat adult immune thrombocytopenia." *American journal of hematology* 88.10 (2013): 858-861.

[62]-Wang, Yan-ming, et al. "The association between antinuclear antibody and response to rituximab treatment in adult patients with primary immune thrombocytopenia." *Hematology* 25.1 (2020): 139-144.

[63]-Baysal, Mehmet, et al. "Could antinuclear antibody positivity be a factor affecting treatment response in immune thrombocytopenia patients on eltrombopag?." *Turkish Journal of Hematology* 39.1 (2022): 38.

[64]-Bernlochner, Isabell, et al. "Impact of immature platelets on platelet response to ticagrelor and prasugrel in patients with acute coronary syndrome." *European heart journal* 36.45 (2015): 3202-3210.

[65]-Benlachgar, Naoufal, et al. "Immature platelets: a review of the available evidence." *Thrombosis research* 195 (2020): 43-50.

[66]-Jeon, Kibum, et al. "Immature platelet fraction: a useful marker for identifying the cause of thrombocytopenia and predicting platelet recovery." *Medicine* 99.7 (2020).

[67]-Ruisi, Mary M., et al. "Stability of measurement of the immature platelet fraction." *American journal of hematology* 85.8 (2010): 622-624.

[68]-Barsam, Sarah J., et al. "Platelet production and platelet destruction: assessing mechanisms of treatment effect in immune thrombocytopenia." *Blood, The Journal of the American Society of Hematology* 117.21 (2011): 5723-5732.

[69]-Blandinières, Adeline, et al. "Usefulness of immature platelet fraction measurement for diagnosis and monitoring of iron deficiency associated thrombocytopenia: about two cases." *Annales de Biologie Clinique*. Vol. 78. No. 4. 2020.

[70]-Negro, Federica, et al. "Impact of gender on immature platelet count and its relationship with coronary artery disease." *Journal of Thrombosis and Thrombolysis* 49 (2020): 511-521.

[71]-Verdoia, Monica, et al. "Impact of aging on immature platelet count and its relationship with coronary artery disease." *Platelets* 31.8 (2020): 1060-1068.

[72]-Hong, Hong, Wenbin Xiao, and Robert W. Maitta. "Steady increment of immature platelet fraction is suppressed by irradiation in single-donor platelet components during storage." *PloS one* 9.1 (2014): e85465.

[73]-Abe, Yasunori, et al. "A simple technique to determine thrombopoiesis level using immature platelet fraction (IPF)." *Thrombosis research* 118.4 (2006): 463-469.

[74]-Adly, Amira Abdel Moneam, et al. "Evaluation of the immature platelet fraction in the diagnosis and prognosis of childhood immune thrombocytopenia." *Platelets* 26.7 (2015): 645-650.

[75]-McDonnell, Alicia, et al. "Utility of the immature platelet fraction in pediatric immune thrombocytopenia: Differentiating from bone marrow failure and predicting bleeding risk." *Pediatric Blood & Cancer* 65.2 (2018): e26812.

[76]-Frelinger III, A. L., et al. "Platelet function in ITP, independent of platelet count, is consistent over time and is associated with both current and subsequent bleeding severity." *Thrombosis and haemostasis* 118.01 (2018): 143-151.

[77]-Tremaroli, Valentina, and Fredrik Bäckhed. "Functional interactions between the gut microbiota and host metabolism." *Nature* 489.7415 (2012): 242-249.

[78]-Pereira, Karla Nunes, et al. "Diagnostic characteristics of immature platelet fraction for the assessment of immune thrombocytopenia." Thrombosis Research 202 (2021): 125-127.

[79]-Ali, Imtiaz, Ciaren Graham, and Nina C. Dempsey-Hibbert. "Immature platelet fraction as a useful marker in the etiological determination of thrombocytopenia." Experimental Hematology 78 (2019): 56-61.

[80]-Serrando, M., et al. "Clinical significance of IPF% measurement in diagnosing thrombocytopenic disorders: distinguishing primary immune thrombocytopenia from other disorders." International Journal of Laboratory Hematology 38.3 (2016): e65-e68.

[81]-Yang, Lei, et al. "Contributions of TRAIL-mediated megakaryocyte apoptosis to impaired megakaryocyte and platelet production in immune thrombocytopenia." Blood, The Journal of the American Society of Hematology 116.20 (2010): 4307-4316.

[82]-Gu, Dongsheng, et al. "Th1 (CXCL10) and Th2 (CCL2) chemokine expression in patients with immune thrombocytopenia." Human immunology 71.6 (2010): 586-591.

[83]-Ku, Fan-Chen, et al. "Stromal-derived factor-1 gene variations in pediatric patients with primary immune thrombocytopenia." European Journal of Haematology 90.1 (2013): 25-30.

[84]-Wang, Jian-Feng, Zhong-Ying Liu, and Jerome E. Groopman. "The α-chemokine receptor CXCR4 is expressed on the megakaryocytic lineage from progenitor to platelets and modulates migration and adhesion." Blood, The Journal of the American Society of Hematology 92.3 (1998): 756-764.

[85]-Saeidi, Sajedeh, et al. "Is there a relationship between CXCR4 gene expression and prognosis of immune thrombocytopenia in children?." Indian Journal of Hematology and Blood Transfusion 33 (2017): 216-221.

[86]-Chevalier, Nina, et al. "CXCR5 expressing human central memory CD4 T cells and their relevance for humoral immune responses." The Journal of Immunology 186.10 (2011): 5556-5568.

[87]-Ansel, K. Mark, Ruth BS Harris, and Jason G. Cyster. "CXCL13 is required for B1 cell homing, natural antibody production, and body cavity immunity." Immunity 16.1 (2002): 67-76.

[88]-Alvarez, Enrique, et al. "CXCL13 is a biomarker of inflammation in multiple sclerosis, neuromyelitis optica, and other neurological conditions." Multiple Sclerosis Journal 19.9 (2013): 1204-1208.

[89]-Jernås, Margareta, et al. "MicroRNA regulate immunological pathways in T-cells in immune thrombocytopenia (ITP)." Blood, The Journal of the American Society of Hematology 121.11 (2013): 2095-2098.

[90]-Li, Jian-Qin, et al. "MicroRNA-125-5p targeted CXCL13: a potential biomarker associated with immune thrombocytopenia." American Journal of Translational Research 7.4 (2015): 772.

[91]-Zhang, Lin, et al. "Immune status and chemokine C receptor 7 expression in primary in patients with immune thrombocytopenia." Turkish Journal of Hematology 39.1 (2022): 29.

[92]-Schneider, Pascal, et al. "BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth." The Journal of experimental medicine 189.11 (1999): 1747-1756.

[93]-Moore, Paul A., et al. "BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator." Science 285.5425 (1999): 260-263.

[94]-Huard, Bertrand, et al. "T cell costimulation by the TNF ligand BAFF." The Journal of Immunology 167.11 (2001): 6225-6231.

[95]-Ye, Qunrui, et al. "BAFF binding to T cell-expressed BAFF-R co-stimulates T cell proliferation and alloresponses." European journal of immunology 34.10 (2004): 2750-2759.

[96]-Huard, Bertrand, et al. "BAFF production by antigen-presenting cells provides T cell co-stimulation." International immunology 16.3 (2004): 467-475.

[97]-Zhu, Xiao-juan, et al. "The effects of BAFF and BAFF-R-Fc fusion protein in immune thrombocytopenia." Blood, The Journal of the American Society of Hematology 114.26 (2009): 5362-5367.

[98]-Khalifa, Khaled AE, et al. "Expression of B-cell activating factor in pediatric patients with immune thrombocytopenia: A single institutional series and review of literature." Journal of Immunoassay and Immunochemistry 44.1 (2023): 41-55.

[99]-Wu, Boting, et al. "CXCL13, CCL4, and sTNFR as circulating inflammatory cytokine markers in primary and SLE-related autoimmune hemolytic anemia." Journal of Translational Medicine 13 (2015): 1-7.

[100]-Velo-García, Alba, Sara Guerreiro Castro, and David A. Isenberg. "The diagnosis and management of the haematologic manifestations of lupus." Journal of autoimmunity 74 (2016): 139-160.

[101]-Provan, Drew, et al. "International consensus report on the investigation and management of primary immune thrombocytopenia." Blood, The Journal of the American Society of Hematology 115.2 (2010): 168-186.

[102]-Aringer, Martin, et al. "2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus." Arthritis & rheumatology 71.9 (2019): 1400-1412.

[103]-Dinarello, Charles A. "Interleukin-1 in the pathogenesis and treatment of inflammatory diseases." Blood, The Journal of the American Society of Hematology 117.14 (2011): 3720-3732.

[104]-Calvani, Nicola, et al. "Th1 cytokines in the pathogenesis of lupus nephritis: the role of IL-18." Autoimmunity reviews 4.8 (2005): 542-548.

[105]-Liang, Dong, et al. "Imbalance of interleukin 18 and interleukin 18 binding protein in patients with lupus nephritis." Cell Mol Immunol 3.4 (2006): 303-306.

[106]-Tucci, Marco, et al. "Glomerular accumulation of plasmacytoid dendritic cells in active lupus nephritis: role of interleukin-18." Arthritis & Rheumatism 58.1 (2008): 251-262.

[107]-Shan, Ning-ning, et al. "Interleukin 18 and interleukin 18 binding protein in patients with idiopathic thrombocytopenic purpura." British journal of haematology 144.5 (2009): 755-761.

[108]-Sutton, Caroline, et al. "A crucial role for interleukin (IL)-1 in the induction of IL-17–producing T cells that mediate autoimmune encephalomyelitis." The Journal of experimental medicine 203.7 (2006): 1685-1691.

[109]-Acosta-Rodriguez, Eva V., et al. "Interleukins 1β and 6 but not transforming growth factor-β are essential for the differentiation of interleukin 17–producing human T helper cells." Nature immunology 8.9 (2007): 942-949.

[110]-Zhan, Yanxia, et al. "Interleukin (IL)-1 family cytokines could differentiate primary immune thrombocytopenia from systemic lupus erythematosus-associated thrombocytopenia." Annals of translational medicine 9.3 (2021).

[111]-Sarrand, Julie, and Muhammad Soyfoo. "Involvement of il-33 in the pathophysiology of systemic lupus erythematosus." International journal of molecular sciences 23.6 (2022): 3138.

[112]-Andersson, J. J. A. P. "Cytokines in idiopathic thrombocytopenic purpura (ITP)." Acta Paediatrica 87 (1998): 61-64.

[113]-Esteller, Manel. "Non-coding RNAs in human disease." Nature reviews genetics 12.12 (2011): 861-874.

[114]-Allegra, Alessandro, et al. "Circular RNA as a novel biomarker for diagnosis and prognosis and potential therapeutic targets in multiple myeloma." Cancers 14.7 (2022): 1700.

[115]-Allegra, Alessandro, et al. "Circulating microRNAs: new biomarkers in diagnosis, prognosis and treatment of cancer." International journal of oncology 41.6 (2012): 1897-1912.

[116]-Warth, Sebastian C., et al. "Induced miR-99a expression represses Mtor cooperatively with miR-150 to promote regulatory T-cell differentiation." The EMBO journal 34.9 (2015): 1195-1213.

[117]-Zhao, Haifeng, et al. "Reduced MIR 130 A is involved in primary immune thrombocytopenia via targeting TGFB 1 and IL 18." British journal of haematology 166.5 (2014): 767-773.

[118]-Chang, Mei, et al. "Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro." Blood 102.3 (2003): 887-895.

[119]-Wang, Juan, et al. "Upregulation of long noncoding RNA TMEVPG1 enhances T helper type 1 cell response in patients with Sjögren syndrome." Immunologic research 64 (2016): 489-496.

[120]-Liu, Wen-Jun, et al. "Role of platelet function and platelet membrane glycoproteins in children with primary immune thrombocytopenia." Molecular medicine reports 14.3 (2016): 2052-2060.

[121]-Zhao, Yuerong, et al. "The Extensive Regulation of MicroRNA in Immune Thrombocytopenia." Clinical and Applied Thrombosis/Hemostasis 28 (2022): 10760296221093595.

[122]-Fan, Zhenwei, et al. "Systematic identification of lncRNA-associated ceRNA networks in immune thrombocytopenia." Computational and Mathematical Methods in Medicine 2020 (2020).

[123]-Tremaroli, Valentina, and Fredrik Bäckhed. "Functional interactions between the gut microbiota and host metabolism." Nature 489.7415 (2012): 242-249.

[124]-Allegra, A., et al. "Role of the microbiota in haematologic malignancies." Neth. J. Med 77.2 (2019): 67-80.

[125]-Allegra, Alessandro, et al. "Interactions between the MicroRNAs and microbiota in cancer development: Roles and therapeutic opportunities." Cancers 12.4 (2020): 805.

[126]-Innao, Vanessa, et al. "New frontiers about the role of human microbiota in immunotherapy: the immune checkpoint inhibitors and CAR T-cell therapy era." International Journal of Molecular Sciences 21.23 (2020): 8902.

[127]-Russell, Jordan T., et al. "Genetic risk for autoimmunity is associated with distinct changes in the human gut microbiome." Nature communications 10.1 (2019): 3621.

[128]-Kouchaki, Ebrahim, et al. "Clinical and metabolic response to probiotic supplementation in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled trial." Clinical nutrition 36.5 (2017): 1245-1249.

[129]-Maeda, Yuichi, and Kiyoshi Takeda. "Role of gut microbiota in rheumatoid arthritis." Journal of clinical medicine 6.6 (2017): 60.

[130]-Zhang, Xuewu, et al. "Gut microbiome and metabolome were altered and strongly associated with platelet count in adult patients with primary immune thrombocytopenia." Frontiers in microbiology 11 (2020): 1550.

[131]-Johnsen, Jill. "Pathogenesis in immune thrombocytopenia: new insights." Hematology 2010, the American Society of Hematology Education Program Book 2012.1 (2012): 306-312.

[132]-Cines, Douglas B., Adam Cuker, and John W. Semple. "Pathogenesis of immune thrombocytopenia." La Presse Médicale 43.4 (2014): e49-e59.

[133]-Toltl, Lisa J., et al. "Piecing together the humoral and cellular mechanisms of immune thrombocytopenia." Seminars in thrombosis and hemostasis. Vol. 37. No. 06. © Thieme Medical Publishers, 2011.

[134]-Panzer, Simon, et al. "Platelet-associated immunoglobulins IgG, IgM, IgA and complement C3 in immune and nonimmune thrombocytopenic disorders." American journal of hematology 23.2 (1986): 89-99.

[135]-Peerschke, Ellinor I., Wei Yin, and Berhane Ghebrehiwet. "Complement activation on platelets: implications for vascular inflammation and thrombosis." Molecular immunology 47.13 (2010): 2170-2175.

[136]-Kayser, W., et al. "Platelet-associated complement C3 in thrombocytopenic states." British journal of haematology 54.3 (1983): 353-363.

[137]-Najaoui, Abderrahim, et al. "Autoantibody-mediated complement activation on platelets is a common finding in patients with immune thrombocytopenic purpura (ITP)." European journal of haematology 88.2 (2012): 167-174.

[138]-Peerschke, Ellinor IB, et al. "Complement activation on platelets correlates with a decrease in circulating immature platelets in patients with immune thrombocytopenic purpura." British journal of haematology 148.4 (2010): 638-645.

[139]-Verschoor, Admar, and Harald F. Langer. "Crosstalk between platelets and the complement system in immune protection and disease." Thrombosis and haemostasis 110.11 (2013): 910-919.

[140]-Lurhuma, A. Z., H. Riccomi, and P. L. Masson. "The occurrence of circulating immune complexes and viral antigens in idiopathic thrombocytopenic purpura." Clinical and Experimental Immunology 28.1 (1977): 49.

[141]-Trent, R. J., et al. "Immune complexes in thrombocytopenic patients: cause or effect?." British Journal of Haematology 44.4 (1980): 645-654.

[142]-Ohali, Meli, et al. "Complement profile in childhood immune thrombocytopenic purpura: a prospective pilot study." Annals of hematology 84 (2005): 812-815.

[143]-Forster, J., Z. Katzikadamos, and P. Zinn. "Platelet-associated IgG, IgM, and C3 in paediatric infectious disease." Helvetica Paediatrica Acta 43.5-6 (1989): 415-422.

[144]-Ruiz-Delgado, Guillermo J., et al. "Abnormalities in the expression of CD55 and CD59 surface molecules on peripheral blood cells are not specific to paroxysmal nocturnal hemoglobinuria." Hematology 14.1 (2009): 33-37.

[145]-Zhu, Xiaolu, et al. "Diminished expression of β2-GPI is associated with a reduced ability to mitigate complement activation in anti-GPIIb/IIIa-mediated immune thrombocytopenia." Annals of Hematology 97 (2018): 641-654.

[146]-Sahip, Birsen, et al. "Higher interleukin 21 level is predictive of relapse in immune thrombocytopenia. Is it associated with activation of the complement system?." British Journal of Haematology 173.2 (2016): 321-323.

[147]-Xu, Chengfeng, et al. "A polygenic stacking classifier revealed the complicated platelet transcriptomic landscape of adult immune thrombocytopenia." Molecular Therapy-Nucleic Acids 28 (2022): 477-487.

[148]-Miltiadous, Oriana, Ming Hou, and James B. Bussel. "Identifying and treating refractory ITP: difficulty in diagnosis and role of combination treatment." Blood, The Journal of the American Society of Hematology 135.7 (2020): 472-490.

[149]-Psaila, Bethan, and James B. Bussel. "Refractory immune thrombocytopenic purpura: current strategies for investigation and management." British journal of haematology 143.1 (2008): 16-26.

[150]-Provan, Drew, et al. "Updated international consensus report on the investigation and management of primary immune thrombocytopenia." Blood advances 3.22 (2019): 3780-3817.

[151]-Rodeghiero, Francesco, et al. "Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group." Blood, The Journal of the American Society of Hematology 113.11 (2009): 2386-2393.

[152]-Neunert, Cindy, et al. "American Society of Hematology 2019 guidelines for immune thrombocytopenia." Blood advances 3.23 (2019): 3829-3866.

[153]-Kim, Dong Jin, and Jae Hee Chung. "Long-term results of laparoscopic splenectomy in pediatric chronic immune thrombocytopenic purpura." Annals of surgical treatment and research 86.6 (2014): 314-318.

[154]-Cuker, Adam, and Cindy E. Neunert. "How I treat refractory immune thrombocytopenia." Blood, The Journal of the American Societ

[155]-Heitink-Polle, Katja MJ, et al. "Clinical and laboratory predictors of chronic immune thrombocytopenia in children: a systematic review and meta-analysis." Blood, The Journal of the American Society of Hematology 124.22 (2014): 3295-3307.

[156]-Bergmann, Anke K., Rachael F. Grace, and Ellis J. Neufeld. "Genetic studies in pediatric ITP: outlook, feasibility, and requirements." Annals of hematology 89.Suppl 1 (2010): 95-103.

[157]-Rischewski, Johannes R., et al. "Idiopathic thrombocytopenic purpura (ITP): is there a genetic predisposition?." Pediatric blood & cancer 47.S5 (2006): 678-680.

[158]-Zhao, Shasha, et al. "Chronic refractory immune thrombocytopenia is associated with variants in immune genes." Clinical and Applied Thrombosis/Hemostasis 27 (2021): 10760296211059813.

[159]-Strowig, Till, et al. "Inflammasomes in health and disease." nature 481.7381 (2012): 278-286.

[160]-Qiao, Jianlin, et al. "Elevated expression of NLRP3 in patients with immune thrombocytopenia." Immunologic research 64 (2016): 431-437.

[161]-Yu, Jie, et al. "NF-κB-94ins/del ATTG genotype contributes to the susceptibility and imbalanced Th17 cells in patients with immune thrombocytopenia." Journal of immunology research 2018 (2018).

[162]-Cooper, Nichola, et al. "Immune thrombocytopenia (ITP) World Impact Survey (I-WISh): impact of ITP on health-related quality of life." American journal of hematology 96.2 (2021): 199-207.

[163]-Pavord, Sue, et al. "Practical guidance for the management of adults with immune thrombocytopenia during the COVID-19 pandemic." British Journal of Haematology 189.6 (2020): 1038-1043.

[164]-Bradbury, Charlotte A., et al. "Mycophenolate mofetil for first-line treatment of immune thrombocytopenia." New England Journal of Medicine 385.10 (2021): 885-895.

[165]-Kuter, David J. "New drugs for familiar therapeutic targets: thrombopoietin receptor agonists and immune thrombocytopenic purpura." European Journal of Haematology 80 (2008): 9-18.

[166]-Li, Junzhi, et al. "Thrombocytopenia caused by the development of antibodies to thrombopoietin." Blood, The Journal of the American Society of Hematology 98.12 (2001): 3241-3248.

[167]-Ghanima, Waleed, et al. "Thrombopoietin receptor agonists: ten years later." Haematologica 104.6 (2019): 1112.

[168]-Al-Samkari, Hanny, and David J. Kuter. "Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia." Therapeutic advances in hematology 10 (2019): 2040620719841735.

[169]-Kuter, David J. "Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia." Annual review of medicine 60 (2009): 193-206.

[170]-Kuter, David J., et al. "Romiplostim or standard of care in patients with immune thrombocytopenia." New England Journal of Medicine 363.20 (2010): 1889-1899.

[171]-Kuter, David J. "The biology of thrombopoietin and thrombopoietin receptor agonists." International journal of hematology 98 (2013): 10-23.

[172]-Kuter, David J., et al. "Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia (ITP) for up to 1 year and in those with chronic ITP for more than 1 year: a subgroup analysis of integrated data from completed romiplostim studies." British Journal of Haematology 185.3 (2019): 503-513.

[173]-Bussel, James B., and Mariana P. Pinheiro. "Eltrombopag." Hematopoietic Growth Factors in Oncology (2010): 289-303.

[174]-Erickson-Miller, Connie L., et al. "Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist." Stem cells 27.2 (2009): 424-430.

[175]-Jurczak, Wojciech, et al. "Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia." British journal of haematology 183.3 (2018): 479-490.

[176]-Cooper, Nichola, et al. "Tapering and discontinuation of thrombopoietin receptor agonist therapy in patients with immune thrombocytopenia: results from a modified Delphi panel." Acta Haematologica 144.4 (2021): 418-426.

[177]-Zaja, F., et al. "Tapering and discontinuation of thrombopoietin receptor agonists in immune thrombocytopenia: Real-world recommendations." Blood Reviews 41 (2020): 100647.

[178]-González-López, Tomás José, et al. "Sustained response after discontinuation of short-and medium-term treatment with eltrombopag in patients with immune thrombocytopenia." Platelets 26.1 (2015): 83-86.

[179]-Provan, D., et al. "Sustained responses following treatment with romiplostim in immune thrombocytopenia: a single-centre experience." J Hematol Thromboembolic Dis 2.04 (2014): 1-3.

[180]-Ghadaki, Bahareh, et al. "Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists." Transfusion 53.11 (2013): 2807-2812.

[181]-Scheinberg, Phillip. "Activity of eltrombopag in severe aplastic anemia." Blood Advances 2.21 (2018): 3054-3062.

[182]-Bussel, James, et al. "Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo-controlled trials." American journal of hematology 93.7 (2018): 921-930.

[183]-Bussel, James B., et al. "Long-term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program." American journal of hematology 94.5 (2019): 546-553.

[184]-Jaime-Pérez, José Carlos, et al. "Insights on chronic immune thrombocytopenia pathogenesis: a bench to bedside update." Blood Reviews 49 (2021): 100827.

[185]-Newland, Adrian C., et al. "Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia." American journal of hematology 95.2 (2020): 178-187.

[186]-Zuercher, Adrian W., et al. "Next-generation Fc receptor–targeting biologics for autoimmune diseases." Autoimmunity reviews 18.10 (2019): 102366.

[187]-Langrish, Claire L., et al. "Preclinical efficacy and anti-inflammatory mechanisms of action of the Bruton tyrosine kinase inhibitor rilzabrutinib for immune-mediated disease." The Journal of Immunology 206.7 (2021): 1454-1468.

[188]-Gavriilaki, Eleni, Régis Peffault de Latour, and Antonio Maria Risitano. "Advancing therapeutic complement inhibition in haematologic diseases: PNH and beyond." Blood, The Journal of the American Society of Hematology 139.25 (2022): 3571-3582.

[189]-Cheloff, Abraham Z., David J. Kuter, and Hanny Al-Samkari. "Serum complement levels in immune thrombocytopenia: characterization and relation to clinical features." Research and Practice in Thrombosis and Haemostasis 4.5 (2020): 807-812.

[190]-Ulrichts, Peter, et al. "Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans." The Journal of Clinical Investigation 128.10 (2018): 4372-4386.

[191]-Robak, Tadeusz, et al. "Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia." Blood advances 4.17 (2020): 4136-4146.

[192]-Crickx, Etienne, et al. "Daratumumab, an original approach for treating multi-refractory autoimmune cytopenia." Haematologica 106.12 (2021): 3198.